BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 2, 2026
Breaking News: BioWorld Science 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Biomarkers

Researchers find de novo CAMK2B variant in patient with tetralogy of Fallot

Nov. 17, 2023
CAMK2B encodes calcium/calmodulin-dependent protein kinase type II subunit β, a kinase expressed in the brain that has an important role in synaptic plasticity. Genetic variations are associated with neurodevelopmental disorders.
Read More
Microscope with beakers and flasks
Drug Design, Drug Delivery & Technologies

Postera and Amgen enter AI-led multitarget collaboration

Nov. 17, 2023
Postera Inc. has announced a multitarget collaboration with Amgen Inc. that seeks to leverage Postera’s artificial intelligence (AI) platform, Proton, an innovation in generative chemistry and synthesis-aware design, and Amgen’s drug discovery expertise, to advance up to five small-molecule programs.
Read More
Genitourinary/Sexual Function

Kanna Health’s KH-001 for premature ejaculation cleared to enter clinic

Nov. 17, 2023
Kanna Health Ltd. has received clearances by the FDA and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its IND application and clinical trial application (CTA), respectively, to initiate a first-in-human phase I trial of KH-001 besylate (KH-001) for premature ejaculation.
Read More
Lab research with pipette, microsope
Immuno-oncology

OR-641 promotes antitumoral responses through LILRB1/LILRB2 dual targeting

Nov. 17, 2023
Oncoresponse Inc. has presented preclinical data on OR-641 as a potential immunotherapeutic for cancer.
Read More
Illustration of pancreas
Endocrine/Metabolic

Fractyl Health announces new research on GLP-1-based pancreatic gene

Nov. 17, 2023
Fractyl Health Inc. has expanded an academic-industry scientific partnership focused on advancing research on the role of the gut and pancreas in metabolic disease.
Read More
Close up of hand scratching arm with psoriasis patches
Dermatologic

Guangzhou Fermion Technology presents data on TYK2 inhibitor

Nov. 17, 2023
Nonreceptor tyrosine-protein kinase TYK2 plays key roles in the signaling of pro-inflammatory molecules such as IL-23, IL-12 or type I IFN, which at the same time play key roles in several immune-mediated diseases such as atopic dermatitis and psoriasis, among others.
Read More
Nephrology

APOL1 inhibitor reverses albuminuria, kidney injury in APOL1 G1/G2 mice

Nov. 17, 2023
It has been previously demonstrated that the two coding variants in the APOL1 gene (G1 and G2) are associated with a greater risk of progressive, proteinuric kidney disease; however, there currently are no therapies to address the causal genetic drivers of this disease. Researchers from Maze Therapeutics Inc. presented the discovery and preclinical characterization of a novel small-molecule inhibitor of APOL1, MZ-302, and they evaluated its efficacy in a new transgenic model of APOL1-mediated kidney disease (AKD).
Read More
Lab cultures of senescent human lung cells.
Infection

Senolytic therapies suppress long COVID in human organoids, mouse models

Nov. 17, 2023
By Tamra Sami
Researchers from the University of Queensland discovered that senolytic therapies can suppress long-COVID neuropathology and long-term disorders caused by viral infections by reducing senescent cells, thereby reducing inflammation. Published Nov. 13, 2023, in Nature, the study examined the use of human pluripotent stem cells to generate small mini human brain organoids to screen for antiaging interventions called senolytics that selectively eliminate senescent cells that accumulate with age, lead author Julio Aguado told BioWorld.
Read More
Real fluorescence microscopic view of human neuroblastoma cells
Biomarkers

Researchers find KAT6B is deleterious variant behind neuroblastoma

Nov. 16, 2023
The GOBACK study analyzed germline susceptibility in children with birth defects and a cancer diagnosis, including a total of 47 probands. Whole-genome sequencing was performed, and researchers evaluated single-nucleotide variants, insertion/deletion variants, as well as copy number variations.
Read More
Neurology/Psychiatric

Fundamental Pharma discovers new TRPM4/NMDA interaction inhibitors for ALS

Nov. 16, 2023
Fundamental Pharma GmbH has described TRPM4/NMDA interaction inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis (ALS).
Read More
Previous 1 2 … 831 832 833 834 835 836 837 838 839 … 18002 18003 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • Depression concept with human, broken brain and heavy rain

    CROI 2026 highlights depression and cognitive vulnerability in HIV

    BioWorld
    The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 24, 2026
  • Concept art for headache

    Slate Medicines launches with focus on headache disorders

    BioWorld Science
    Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing